Articles related to Pharmacy (Community)

The American College of Physicians issued a living clinical guideline recommending semaglutide and tirzepatide as first-line pharmacologic treatments with lifestyle modifications for nonpregnant adults with obesity (BMI 30 kg/m2 or higher) or overweight (BMI 27 to 30 kg/m2) with at least one weight-related comorbidity, with phentermine-topiramate, liraglutide, and naltrexone-bupropion designated as second-, third-, and fourth-line options respectively based on GRADE evidence review.

The Main Street Pharmacy Access Act (H.R. 3164/S. 2426), which would authorize Medicare reimbursement for pharmacist-provided testing and treatment of flu, strep, RSV, and COVID-19 in states that already permit those services, cleared the House Committee on Ways and Means on May 21 with more than 110 congressional co-sponsors and support from over 170 organizations.

Breckenridge Pharmaceutical initiated a voluntary Class II recall of duloxetine delayed-release capsules 60 mg (Lot 241069C, expiration May 31, 2027) on April 21, 2026, following detection of elevated N-nitroso-duloxetine impurity levels attributed to CGMP deviations at the Barcelona manufacturing site, affecting 165,761 bottles distributed nationwide.

Cotrimoxazole was associated with nearly twice the adverse event rate of fluoroquinolones in a retrospective study of 228 hospitalized men aged 75 or older with urinary tract infections, with acute kidney injury onset occurring at a median of six days post-initiation.

Hemarthrosis affects an estimated 70–80% of people with hemophilia and can progress to permanent joint damage, with pain management presenting a specific medication safety intersection point for pharmacists at the OTC counter and bedside.

US prescription drug expenditures reached $915.2 billion in 2025, with utilization growth rather than price increases accounting for the majority of the 12.7% rise, and clinic-sector spending projected to outpace hospital spending by a factor of three in 2026.